Associated tags: Research, Safety, Biotechnology, Sec61, Health, Immunosuppression, Pharmaceutical industry, Science, Oncology, Patient, Disease, Lupus nephritis, Degenerative disease, Pharmaceutical, Clinical Trials, Diagnosis, Dialysis, UPCR, Clinical trial
Research,
Clinical Trials,
Biotechnology,
Other Health,
Health,
Pharmaceutical,
Other Science,
Science,
Oncology,
ASN,
Disease,
Lupus nephritis,
Pathology,
Lee,
Ohio State University Wexner Medical Center,
Degenerative disease,
Society,
FACP,
Patient,
Division,
Annual general meeting,
Nasdaq,
Treatment,
MD,
Immunosuppression,
Sec61,
Congress,
Safety,
2021 Essex County Council election,
Associate,
International Association for Mission Studies,
Ohio State University,
FASN,
Medicine,
List of life sciences,
Pharmaceutical industry,
Nephrology Of note, the Phase 2 MISSION poster will include the full data set from the concluded study, with all 17 evaluable patients completing the 37-week trial.
Key Points:
- Of note, the Phase 2 MISSION poster will include the full data set from the concluded study, with all 17 evaluable patients completing the 37-week trial.
- There will be additional MISSION data included in the poster presentation that are not available in the abstract.
- Following the conference, the presentation materials will be available in the Scientific Publications section of Kezar Life Sciences website at www.kezarlifesciences.com .
- Zetomipzomib, its lead development asset, is a selective immunoproteasome inhibitor being evaluated in a Phase 2 clinical trial in lupus nephritis.
Oncology,
Health,
FDA,
General Health,
Clinical Trials,
Pharmaceutical,
Biotechnology,
Inflammation,
Association,
Disease,
Lupus nephritis,
Conditional sentence,
Indiana University,
U.S. Securities and Exchange Commission,
Mortality,
ALT,
Assistant,
Physician,
Nasdaq,
IND,
Private Securities Litigation Reform Act,
Food,
AST,
Liver,
Cataract,
Prednisone,
Autoimmune hepatitis,
Polymyositis,
Immune system,
Lupus,
List of life sciences,
Week,
Hepatocellular carcinoma,
Safety,
Immunosuppression,
Regulation of food and dietary supplements by the U.S. Food and Drug Administration,
Quality of life,
Program,
Cirrhosis,
Liver failure,
Dermatomyositis,
Patient,
AIH,
Forward-looking statement,
Sec61,
Degenerative disease,
Diabetes,
Pharmaceutical industry,
Vaccine,
Medicine Standard of care treatment for AIH is immunosuppressive treatment with chronic corticosteroids that can lead to additional morbidity and mortality.
Key Points:
- Standard of care treatment for AIH is immunosuppressive treatment with chronic corticosteroids that can lead to additional morbidity and mortality.
- There is a significant need for treatment regimens that reduce or remove the need for chronic immunosuppression using corticosteroids.
- Zetomipzomib is a unique small molecule with the potential to be a non-immunosuppressive, anti-inflammatory treatment for multiple autoimmune diseases.
- Kezar Life Sciences is a clinical-stage biopharmaceutical company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders.
Retrieved on:
Thursday, September 29, 2022
Oncology,
Health,
General Health,
Clinical Trials,
Research,
Science,
Biotechnology,
ACR,
Safety,
Immunosuppression,
American College,
MD,
Sec61,
Oklahoma Medical Research Foundation,
American College of Rheumatology,
Lupus nephritis,
Patient,
List of life sciences,
RA,
2021 Essex County Council election,
Nasdaq,
Congress,
Degenerative disease,
Health services research,
Lupus,
Disease,
Arthritis,
Health care,
Pharmaceutical industry,
Spondyloarthropathy There will be additional MISSION data included in the poster presentation that are not available in the abstract.
Key Points:
- There will be additional MISSION data included in the poster presentation that are not available in the abstract.
- Following the conference, the presentation materials will be available in the Scientific Publications section of Kezar Life Sciences website at www.kezarlifesciences.com .
- Kezar Life Sciences is a clinical-stage biopharmaceutical company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders.
- Zetomipzomib, its lead development asset, is a selective immunoproteasome inhibitor being evaluated in a Phase 2 clinical trial in lupus nephritis.
Retrieved on:
Thursday, August 11, 2022
Oncology,
Health,
Infectious Diseases,
Research,
Science,
Pharmaceutical,
Biotechnology,
Lupus nephritis,
U.S. Securities and Exchange Commission,
ORR,
Clinical trial,
Leadership,
Research,
Patient,
Translational research,
Tumor microenvironment,
Immunosuppression,
Disease,
UPCR,
American Association,
Risk,
Diagnosis,
Annual general meeting,
Private Securities Litigation Reform Act,
Congress,
American Association for Cancer Research,
Week,
Sec61,
Proteinuria,
List of life sciences,
Partnership,
CRR,
Kezar Pavilion,
Safety,
Pharming,
Pharmacokinetics,
Death,
Dialysis,
Drug discovery,
SLE,
Forward-looking statement,
Autoimmunity,
Growth,
LLC,
Cell,
COVID-19,
Chronic kidney disease,
AACR,
Total,
Degenerative disease,
Association,
Science,
EGFR,
EULAR,
Company,
Pharmaceutical industry,
Medical imaging,
Vaccine,
LN (Nasdaq: KZR ), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today reported financial results for the second quarter ended June 30, 2022 and provided a business update.
Key Points:
- (Nasdaq: KZR ), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today reported financial results for the second quarter ended June 30, 2022 and provided a business update.
- In June 2022, Kezar reported topline results from the open-label MISSION Phase 2 clinical trial evaluating zetomipzomib in patients with active LN.
- Research and development expenses for the second quarter of 2022 increased by $2.0 million to $11.3 million compared to $9.3 million in the second quarter of 2021.
- General and administrative expenses for the second quarter of 2022 increased by $1.3 million to $5.0 million compared to $3.7 million in the second quarter of 2021.
Science,
Other Science,
Biotechnology,
Research,
Pharmaceutical,
Oncology,
Health,
Clinical Trials,
Diagnosis,
Death,
Fever,
Migraine,
Patient,
ORR,
SLE,
Dialysis,
Immunosuppression,
Biomarker,
EGFR,
Nausea,
Șaeș,
CRR,
U.S. Securities and Exchange Commission,
Disease,
UPCR,
Vomiting,
Acute kidney injury,
Chronic kidney disease,
Degenerative disease,
Association,
Risk,
Investor,
Sec61,
Headache,
Clinical trial,
Private Securities Litigation Reform Act,
List of life sciences,
EOT,
Glomerular filtration rate,
Proteinuria,
Nasdaq,
Lupus nephritis,
Urinary tract infection,
Autoimmune disease,
Week,
Lupus,
Webcast,
Injection site reaction,
Safety,
Forward-looking statement,
Pharmaceutical industry,
Medical imaging,
LN The MISSION Phase 2 topline results show a clinically meaningful overall renal response to zetomipzomib after 6 months, without high-dose induction therapy.
Key Points:
- The MISSION Phase 2 topline results show a clinically meaningful overall renal response to zetomipzomib after 6 months, without high-dose induction therapy.
- Based on the strength of these results, we plan to continue developing zetomipzomib for patients with lupus nephritis, as well as evaluate development opportunities for systemic lupus erythematosus.
- The MISSION Phase 2 clinical trial is an open-label study designed to demonstrate the responder rate of zetomipzomib in patients with active LN.
- Patients in the MISSION Phase 2 clinical trial received zetomipzomib without induction therapy, which represents a significant difference from other recently published trials in LN.
Oncology,
Health,
Clinical Trials,
Research,
Science,
Pharmaceutical,
Biotechnology,
Disease,
OLE,
Research,
U.S. Securities and Exchange Commission,
Pharmacokinetics,
Cell,
Lupus nephritis,
American Association,
Private Securities Litigation Reform Act,
LLC,
Drug discovery,
PM,
Annual general meeting,
Degenerative disease,
Chronic kidney disease,
Disclosure,
List of life sciences,
EULAR,
Clinical trial,
European,
COVID-19,
Translational research,
Death,
Company,
Doctor of Philosophy,
Autoimmunity,
Kezar Pavilion,
SLE,
Patient,
Dialysis,
Association,
Total,
DM,
Data collection,
Congress,
Inflammation,
Risk,
American Association for Cancer Research,
Tumor microenvironment,
AACR,
Science,
TIS,
Sec61,
UPCR,
Forward-looking statement,
Safety,
PRR,
Diagnosis,
Immunosuppression,
CEO,
Pharmaceutical industry,
Vaccine,
LN,
Rheumatology (Nasdaq: KZR ), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today reported financial results for the first quarter ended March 31, 2022 and provided a business update.
Key Points:
- (Nasdaq: KZR ), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today reported financial results for the first quarter ended March 31, 2022 and provided a business update.
- In November 2021, Kezar reported interim data from the MISSION Phase 2 open-label trial in patients with active, proliferative LN.
- The virtual presentation will be available beginning Wednesday, June 1, 2022, at 2:00 am Eastern Time through July 31, 2022.
- Kezar Life Sciences is a clinical-stage biopharmaceutical company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders.
Oncology,
Health,
Clinical Trials,
Research,
Science,
Pharmaceutical,
Biotechnology,
Dermatomyositis,
COVID-19,
Forward-looking statement,
Private Securities Litigation Reform Act,
Interim,
Mortality,
U.S. Securities and Exchange Commission,
Myopathy,
Polymyositis,
Safety,
Patient,
Autoimmune disease,
Immunosuppression,
TIS,
Lupus nephritis,
Inflammation,
Degenerative disease,
Skin,
Face,
OLE,
Respiration,
PRR,
Association,
Disease,
PM,
CEO,
Sec61,
Muscle,
Pharmaceutical industry,
Kezar Stadium No additional safety or tolerability issues have been observed, and mean TIS scores have improved over scores observed at the 32-week conclusion of PRESIDIO.
Key Points:
- No additional safety or tolerability issues have been observed, and mean TIS scores have improved over scores observed at the 32-week conclusion of PRESIDIO.
- The company plans to report the MISSION Phase 2 topline data in lupus nephritis (LN) at a Kezar corporate event in June 2022.
- In addition to PRESIDIO, Kezar is conducting the MISSION Phase 2 trial in patients with lupus nephritis.
- Zetomipzomib, its lead development asset, is a selective immunoproteasome inhibitor being evaluated in Phase 2 clinical trials in lupus nephritis, dermatomyositis and polymyositis.
Oncology,
Health,
Infectious Diseases,
Other Health,
Pharmaceutical,
Biotechnology,
Private Securities Litigation Reform Act,
Risk,
SLE,
Biomarker,
Degenerative disease,
Research,
Association,
International,
Lupus nephritis,
Disease,
Dialysis,
Dermatomyositis,
Diagnosis,
Immunosuppression,
American Association,
UPCR,
Annual general meeting,
International nonproprietary name,
U.S. Securities and Exchange Commission,
List of life sciences,
Respiration,
Autoimmunity,
Chronic kidney disease,
Forward-looking statement,
Death,
Clinical trial,
Pharmacokinetics,
Mortality,
Myopathy,
Kezar Pavilion,
AACR,
TIS,
Inflammation,
Disclosure,
American Association for Cancer Research,
Muscle,
Drug discovery,
INN,
Patient,
Total,
Cell,
PM,
Skin,
Tumor microenvironment,
Proteinuria,
Safety,
Data collection,
COVID-19,
Sec61,
Pharmaceutical industry,
Construction,
Vaccine,
LN,
Polymyositis,
Zetomipzomib (KZR-616),
KZR-261,
Lupus Nephritis,
Dermatomyositis and Polymyositis,
Inhibition of Protein Secretion,
Kezar Life Sciences,
ZETOMIPZOMIB (KZR-616),
KZR-261,
LUPUS NEPHRITIS,
DERMATOMYOSITIS AND POLYMYOSITIS,
INHIBITION OF PROTEIN SECRETION,
KEZAR LIFE SCIENCES Kezar Life Sciences, Inc ., (Nasdaq: KZR ), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today reported financial results for the fourth quarter and year ended December 31, 2021 and provided a business update.
Key Points:
- Kezar Life Sciences, Inc ., (Nasdaq: KZR ), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today reported financial results for the fourth quarter and year ended December 31, 2021 and provided a business update.
- The MISSION Phase 2 open-label trial in patients with active, proliferative LN reached target enrollment of 20 patients in November 2021.
- Research and development expenses for the fourth quarter of 2021 increased by $1.7 million to $9.8 million compared to $8.1 million in the fourth quarter of 2020.
- General and administrative expenses for the fourth quarter of 2021 increased by $1.3 million to $4.3 million compared to $3.0 million in the fourth quarter of 2020.
